Dr. Haura codirects the Moffitt Chemical Biology and Molecular Medicine Program and is the Director of the Moffitt Lung Cancer Center of Excellence. He received his B.S. degree in biomedical engineering from the Johns Hopkins University and completed medical school at Duke University School of Medicine. He completed a residency program in internal medicine at Johns Hopkins and then returned to Duke to pursue a clinical fellowship in hematology and oncology, where he was also a research fellow in genetics. His major contribution has been in advancing the field of translational cancer proteomics and molecular characterization of cancers using highly integrative mass spectrometry–based proteomics. He has characterized kinase signaling in cancer, focusing on Src and STAT signaling pathways. He has developed approaches to discern mechanisms of complex drugs in cancer combining chemical and phosphoproteomics and has described kinase function through integrated RNA interference and global mass spectrometry–based proteomics. He is active in developing approaches to characterize and target protein interactomes as well as developing biomarker strategies that exploit the human interactome. Dr. Haura is an expert in the management of lung cancer. He has designed and executed numerous clinical trials exploring new agents for the treatment of lung cancer. He is interested in biomarkers to predict therapeutic responses in lung cancer and is active in developing molecular-based therapeutic clinical trials.
Eric Bruce Haura, MD